Structure via PubChem · Public domain (PubChem)
zanubrutinib
Sign in to saveAlso known as BGB-3111, Brukinsa
Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth.
Chemical data
- Formula
- C27H29N5O3
- Molecular weight
- 471.5 g/mol
- IUPAC name
- (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
- SMILES
- C=CC(=O)N1CCC(CC1)[C@@H]2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
- InChIKey
- RNOAOAWBMHREKO-QFIPXVFZSA-N
- XLogP
- 3.5
- Polar surface area
- 102 Ų
- H-bond donors
- 2
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2019
- Admin. routes
- oral
- Indications
- chronic lymphocytic leukemia, neoplasm of mature B-cells, diffuse large B-cell lymphoma, leukemia
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 471.227039788
- Has use
- medication
Show 6 more facts
- Commons category
- Zanubrutinib
- isomeric SMILES
- C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1
- chemical formula
- C₂₇H₂₉N₅O₃
- canonical SMILES
- C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1
- subject has role
- protein kinase inhibitors
- medical condition treated
- mantle cell lymphoma
Sources (2)
via Wikidata · CC0
~7 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Adverse Effects
- History
- Society and culture
- Legal status
- Synthesis
- References
- External links
Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth.
It was approved for medical use in the United States in November 2019. Zanubrutinib is a therapeutic alternative on the World Health Organization's List of Essential Medicines.
Excerpted from Wikipedia’s “zanubrutinib” article, available under the CC BY-SA 4.0 licence.